Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from TESARO.

Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP Inhibitors

Release Date: June 30, 2019
Expiration Date: June 30, 2020
Media: Internet - based

Activity Overview

This continuing medical education (CME)–certified online activity, “Oncology Briefings™: A Nurses’ Guide to Managing Adverse Events Associated with PARP Inhibitors,” developed in Physicians’ Education Resource®, LLC, established Oncology Briefings™ legacy format, is a monograph publication that includes a summary of key evidence that shapes the application of PARP inhibition strategies for the management of ovarian cancer. Paula J. Anastasia, RN, MN, AOCN, discusses current and emerging treatment options for the treatment of ovarian cancer using PARP inhibitors, emphasizes the keys to managing adverse events, and provides strategies for counseling patients to optimize adherence and patient outcomes.

Benefits of Participating

  • Increase knowledge on the clinical trials that have evaluated PARP inhibitors for ovarian cancer treatment
  • Improve competence identifying practical strategies to manage adverse events encountered with the use of PARP inhibitors for the treatment of patients with ovarian cancer
  • Improve understanding related to the timing and selection of molecular testing methods for patients with ovarian cancer
  • Increase knowledge on emerging approaches for the management of patients with ovarian cancer treated with PARP inhibitors

CME Activity Table of Contents

  • Pre Test
  • Activity
  • Post Test
  • Evaluation and Request for Credit

Acknowledgement of Commercial Support

This activity is supported by an educational grant from TESARO.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward advanced practitioners, nurses, and other healthcare professionals interested in the multidisciplinary treatment and management of ovarian cancer patients treated with PARP inhibitors.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Outline recent safety and efficacy data pertaining to the application of PARP inhibitors in the setting of ovarian cancer.
  • Develop evidence-based strategies to effectively manage predictable adverse events associated with PARP inhibitor therapy.
  • Summarize elements for effective counseling strategies for patients who may be candidates for PARP inhibitor therapy.

Faculty, Staff, and Planners’ Disclosures


Paula J. Anastasia
Paula J. Anastasia, MN, RN, AOCN
Gynecology-Oncology Clinical Nurse Specialist
Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Disclosures: Speakers Bureau: Genentech.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By